Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support

News & Events

Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support on Canadian biotech company creation and success. Montreal, November 11th, 2019 – CQDM commends Encycle Therapeutics for their acquisition by Zealand Pharma (NASDAQ: ZEAL)[1]. CQDM is proud to have supported Encycle Therapeutics and its technology platform from the very beginning in partnership with Toronto Innovation Acceleration Partnership … Read More

We are RECRUITING ! Interested in an Administrative Coordinator position ? Apply now !

News & Events

Since its creation, CQDM has raised nearly $100 million to fund the development of approximately 80 outstanding technologies addressing major health challenges, including cancer, neurodegenerative and metabolic diseases. CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading pharmaceutical organizations, several … Read More

CQDM, the CCS and Theratechnologies grant $1.7M to UQAM in breast cancer research

News & Events

CQDM, the Canadian Cancer Society and Theratechnologies grant $1.7M to UQAM for the development of a new therapy targeting the most aggressive form of breast cancer Montreal, October 4, 2019. – CQDM, in partnership with the Canadian Cancer Society (CCS) and Theratechnologies, is proud to announce that it will be granting $1.7M to Université du Québec à Montréal (UQAM) to … Read More

New appointments to CQDM’s Board of Directors and Scientific Advisory Board

News & Events

New appointments to CQDM’s Board of Directors and Scientific Advisory Board Montreal, September 23, 2019 – The chairman of the Board of Directors, Richard Fajzel, and Diane Gosselin, President and CEO of CQDM, are very pleased to announce the appointment of four new members overseeing CQDM’s governance. Daniel Hétu, Managing Director of Lumira Ventures, Sarah Jenna, co-founder and CEO of My … Read More

PARTENAR-IA – * New * Grants for IA research projects applied to the biopharmaceutical sector

News & Events

PARTENAR-IA, a funding initiative to support public-private AI-based research projects ! DEADLINE: OCTOBER 15th, 2019 Montreal, August 20th, 2019 – The PARTENAR-IA initiative aims to accelerate the design and development of Artificial Intelligence (AI) technologies applicable in the biopharmaceutical sector by participating in the funding of collaborative research projects carried out in a Quebec public research institution. The grant can reach … Read More

We are RECRUITING ! Interested in a Senior Director, Business Development position ? Apply now !

News & Events

ABOUT CQDM CQDM is a meeting ground for all stakeholders in biopharmaceutical research. Its principal mission is to fund research projects carried out in partnership between the academic and private sectors. An innovative Canadian initiative, CQDM has two major goals: to accelerate the drug discovery process and to develop safer and more effective drugs. CQDM is funded through contributions from … Read More

SynergiQc-International: New funding opportunity for public-private biopharmaceutical research

News & Events

The SynergiQc-International program is geared to support public/private research with partners outside the province of Quebec ! DEADLINE: OCTOBER 7th, 2019 Montreal, July 16th, 2019 – CQDM has launched the SynergiQc-International funding program that may cover up to 50% of R&D expenses incurred in Quebec as part of a public/private partnership in the biopharmaceutical field, up to a maximum of $500,000. … Read More

Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics

News & Events

Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics, to improve a novel intracellular delivery technology Philadelphia, June 4th, 2019 – CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan … Read More

Contribution from the MEI ($3.3M) allows CQDM to support 5 biopharmaceutical research projects ($15.5M)

News & Events

These highly innovative technologies will address unmet medical needs in cancer and diabetes Philadelphia, June 4th, 2019 – Thanks to a C$3.3M contribution from the MEI, and the participation of several partners, CQDM is proud to announce the funding of five collaborative research projects totaling C$15.5M. Headed by world-class experts in the field of cancer and diabetes, these projects include cutting-edge disciplines … Read More

The CCS, CQDM and biotech companies will invest nearly $10M to support 3 breast cancer research projects

News & Events

Montreal, June 1, 2019 – The Canadian Cancer Society (CCS), a leading breast cancer research funder, and CQDM, a Quebec research consortium whose mission is to fund the development of biopharmaceutical technologies and drugs, are proud to announce that nearly $10 million will be invested to fund three breast cancer research projects over the next three years. “The research partnership … Read More